TY - JOUR
KW - Buprenorphine/therapeutic use
KW - Counseling
KW - General Practitioners
KW - Humans
KW - Malaysia
KW - Naloxone/therapeutic use
KW - Narcotic Antagonists/therapeutic use
KW - Behavioral counseling
KW - HIV risk reduction
KW - buprenorphine treatment
KW - Contingency management
KW - general medical practice
KW - opioid use disorder
AU - R. S. Schottenfeld
AU - M. C. Chawarski
AU - M. Mazlan
A1 - 
AD - Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine, Washington, DC, USA.; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.; Kuala Lumpur, Malaysia.
BT - Addiction (Abingdon, England)
C5 - Education & Workforce; Healthcare Disparities; Measures; Opioids & Substance Use
CP - 8
CY - England
DO - 10.1111/add.15399
IS - 8
JF - Addiction (Abingdon, England)
LA - eng
M1 - Journal Article
PB - Society for the Study of Addiction
PP - England
PY - 2021
SN - 1360-0443; 0965-2140
SP - 2135
EP - 2149
EP - 
T1 - Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners' offices in Malaysia: a randomized, open-label clinical trial
T2 - Addiction (Abingdon, England)
TI - Behavioral counseling and abstinence-contingent take-home buprenorphine in general practitioners' offices in Malaysia: a randomized, open-label clinical trial
U1 - Education & Workforce; Healthcare Disparities; Measures; Opioids & Substance Use
U2 - 33404150
U3 - 10.1111/add.15399
VL - 116
VO - 1360-0443; 0965-2140
Y1 - 2021
Y2 - Aug
ER -